Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...
Kisqali is a selective cyclin-dependent kinase inhibitor that targets proteins involved in the rapid division of cancer cells ...
Graham Parry has given his Hold rating due to a combination of factors surrounding Novartis AG’s recent approval of Kisqali. The drug’s approval for use in early breast cancer with a broad label was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback